Actualités Fortress Biotech Inc - FBIO | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended...

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Mustang Bio Announces Closing of $8 Million Public Offering

WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Mustang Bio Announces Pricing of $8 Million Public Offering

WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in...

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...

Mustang Bio Announces Reverse Stock Split

WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible...

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Fortress Biotech Inc (FBIO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

FBIO Actualités

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Mustang Bio Announces Reverse Stock Split

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Fortress Biotech Inc (FBIO) Actualités

Fortress Biotech Inc (FBIO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

FBIO Actualités

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Mustang Bio Announces Reverse Stock Split

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités